{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:47:24Z","timestamp":1790628444988,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001167","name":"Larry L. Hillblom Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR001444"],"award-info":[{"award-number":["KL2TR001444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01DK118278\\u201301"],"award-info":[{"award-number":["1R01DK118278\\u201301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK139356"],"award-info":[{"award-number":["R01DK139356"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacl.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:09:56Z","timestamp":1750277396000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Insights from a real-world experience with inclisiran at a large United States lipid clinic"],"prefix":"10.1016","author":[{"given":"Donya","family":"Mazdeyasnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-9075","authenticated-orcid":false,"given":"Antoinette","family":"Birs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-9985","authenticated-orcid":false,"given":"Tommy","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1464-5627","authenticated-orcid":false,"given":"Lara","family":"Diano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3800-7369","authenticated-orcid":false,"given":"Michael J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.06.015_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.06.015_bib0002","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.015_bib0003","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.06.015_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032031","article-title":"Harnessing RNA interference for cholesterol lowering: the bench-to-bedside story of inclisiran","volume":"13","author":"Wilkinson","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.06.015_bib0005","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Writing","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.015_bib0006","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta","year":"2023","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacl.2025.06.015_bib0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","article-title":"Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic","volume":"17","author":"Chiou","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.06.015_bib0008","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacl.2025.06.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002184","article-title":"Lipid lowering with inclisiran: a real-world single-centre experience","volume":"9","author":"Padam","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.jacl.2025.06.015_bib0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","article-title":"First clinical experiences with inclisiran in a real-world setting","volume":"17","author":"Mulder","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.06.015_bib0011","doi-asserted-by":"crossref","first-page":"e1096","DOI":"10.1016\/j.jacl.2024.07.008","article-title":"Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems","volume":"18","author":"Wei","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"25","key":"10.1016\/j.jacl.2025.06.015_bib0012","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-mono randomized clinical trial","volume":"S0735-1097","author":"Taub","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.06.015_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:04:10Z","timestamp":1753243450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":13,"alternative-id":["S1933287425003265"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.06.015","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights from a real-world experience with inclisiran at a large United States lipid clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}